最新临床试验：联合化疗是否联用替西罗莫司对中危横纹肌肉瘤的疗效对比

这是经美国国家癌症研究所批准的一项多中心三期临床随机对照试验，目的是研究联合化疗（硫酸长春新碱、达克汀霉素、环磷酰胺交替使用硫酸长春新碱和盐酸伊立替康或长春瑞滨）是否联用替西罗莫司对治疗横纹肌肉瘤（形成于软组织的癌症，如肌肉）患者的疗效。（中等危险）治疗后也有中等几率的恢复。化疗中使用的药物以不同的方式阻止肿瘤细胞的生长，或者杀死肿瘤细胞，阻止肿瘤细胞分裂，或者阻止肿瘤细胞扩散。联合化疗联用替西罗莫司可能通过阻断细胞生长所需的某些酶来阻止肿瘤细胞的生长。目前尚不清楚联合化疗联用替西罗莫司治疗中危横纹肌肉瘤是否更有效。

该临床试验在全美307家医院进行开展。

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy or combination chemotherapy plus temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.

Trial IDs